Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Ma

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Metabolism: Clinical and Experimental|February 22, 2018
GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscleMarta Montori-Grau, Robert Pedreira-Casahuga, Zoé Boyer-Díaz, et al.
Molecular Metabolism|February 5, 2016
Adipose tissue glycogen accumulation is associated with obesity-linked inflammation in humansVictòria Ceperuelo-Mallafré, Miriam Ejarque, Carolina Serena, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
The Lancet. Oncology|December 1, 2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P Iyer, R Alejandro Sica, P Joy Ho, et al.
Bioanalysis|February 3, 2021
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (<u>Part 3</u> - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)Bart Corsaro, Tong-Yuan Yang, Rocio Murphy, et al.
Frontiers in Cell and Developmental Biology|June 3, 2026
Correction: Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathyJuliana Ribeiro-Constante, Alba Tristán-Noguero, Fernando Francisco Martínez Calvo, et al.
Frontiers in Cell and Developmental Biology|March 20, 2024
Developmental outcome of electroencephalographic findings in <i>SYNGAP1</i> encephalopathyJuliana Ribeiro-Constante, Alba Tristán-Noguero, Fernando Francisco Martínez Calvo, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Metabolism: Clinical and Experimental|February 22, 2018
GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscleMarta Montori-Grau, Robert Pedreira-Casahuga, Zoé Boyer-Díaz, et al.
Molecular Metabolism|February 5, 2016
Adipose tissue glycogen accumulation is associated with obesity-linked inflammation in humansVictòria Ceperuelo-Mallafré, Miriam Ejarque, Carolina Serena, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
The Lancet. Oncology|December 1, 2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P Iyer, R Alejandro Sica, P Joy Ho, et al.
Bioanalysis|February 3, 2021
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (<u>Part 3</u> - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)Bart Corsaro, Tong-Yuan Yang, Rocio Murphy, et al.
Frontiers in Cell and Developmental Biology|June 3, 2026
Correction: Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathyJuliana Ribeiro-Constante, Alba Tristán-Noguero, Fernando Francisco Martínez Calvo, et al.
Frontiers in Cell and Developmental Biology|March 20, 2024
Developmental outcome of electroencephalographic findings in <i>SYNGAP1</i> encephalopathyJuliana Ribeiro-Constante, Alba Tristán-Noguero, Fernando Francisco Martínez Calvo, et al.
Pageof 6